Estrogen May Reduce Colorectal Cancer Risk in Postmenopausal Women

Publication
Article
OncologyONCOLOGY Vol 13 No 1
Volume 13
Issue 1

Hormone replacement therapy may reduce the risk of colorectal cancer in women, according to new results of a meta-analysis presented at the North American Menopause Society meeting.

Hormone replacement therapy may reduce the risk of colorectal cancer in women, according to new results of a meta-analysis presented at the North American Menopause Society meeting.

From the first quantitative review of 18 epidemiologic studies done in the United States and Europe of the effects of hormone replacement therapy on colorectal cancer rates in postmenopausal women, Harvard University researcher Meir Stampfer, md, drph, found that women currently taking estrogen had up to a 34% reduction in colorectal cancer rates compared with women who had never used hormones. Overall, there was a 20% reduction in the rate of colon cancer and a 15% reduction in the rate of rectal cancer among women who had taken estrogen at some point in their lives. “Our analysis strongly suggests estrogen replacement therapy can help reduce the risk of colorectal cancer,” said Stampfer.

“This research finding, although provocative, does not eliminate the need for colorectal cancer screening, which currently is the only proven way to prevent colorectal cancer,” said Randall W Burt, md, professor of medicine, University of Utah; program head, Huntsman Cancer Institute; and a member of the AGA governing board. “Colorectal cancer screening for postmenopausal women should be taken as seriously as mammograms and Pap smears.”

Possible Mechanism

Although researchers are not certain how estrogen affects the colon, it is possible that it alters the production of bile acids that aid digestion in the colon and seem to be important for colorectal cancer. In addition, estrogen interacts with estrogen-specific receptors that line the colon and could suppress the growth of abnormal cells.

Both Drs. Burt and Stampfer agree that further studies are needed to determine why estrogen may protect postmenopausal women against colorectal cancer and to shed light on how physicians might prevent the disease in the future.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content